DAIICHI SANKYO CO LTD | 13,92 Euro | +0,12 +0,87 % | |
| WKN: A0F57T ISIN: JP3475350009 Ticker-Symbol: D4S | Berlin | 24.05.13 | 08:14 Uhr |
Branche PharmaAktienmarkt NIKKEI-225 |
|
| Zeit | Aktuelle Nachrichten
Sprache: | Leser | Medien | |
|---|---|---|---|---|
| 17:34 | Indian Billionaire Brothers Prepare To Fight Daiichi Sankyo | 1 | Forbes | |
| 08:33 | Daiichi Sankyo's claims false, baseless: Malvinder Singh | 2 | moneycontrol.com | |
| 23.05. | UPDATE 1-Ranbaxy slumps after Daiichi Sankyo says was misled | 2 | Reuters.com | |
| 23.05. | Ranbaxy shares slump after Daiichi Sankyo says misled over probes | 2 | Reuters.com | |
| 22.05. | Daiichi Sankyo says it was misled over Ranbaxy probes | 3 | Reuters.com | |
| 17.05. | World Hypertension Day 2013: New Sevikar® data and the Daiichi Sankyo patient support programme highlight importance of effective blood pressure management | 122 | news aktuell | |
| Munich, Germany (ots) - * Lack of patient adherence to hypertension treatment is one of the root causes of failure to reach blood pressure goals, contributing to increased risk of serious cardiovascular... Mehr lesen zu: World Hypertension Day 2013: New Sevikar® data and the Daiichi Sankyo patient support programme highlight importance of effective blood pressure management | ||||
| 17.05. | World Hypertension Day 2013: New Sevikar Data and the Daiichi Sankyo Patient Support Programme Highlight Importance of Effective Blood Pressure Management | 103 | PR Newswire | |
| MUNICH, May 17, 2013 /PRNewswire/ --
Lack of patient adherencetohypertension treatment is one of the root causes of failuretoreach blood pressure goals, contributingtoincreased risk of serious... Mehr lesen zu: World Hypertension Day 2013: New Sevikar Data and the Daiichi Sankyo Patient Support Programme Highlight Importance of Effective Blood Pressure Management | ||||
| 14.05. | Daiichi Sankyo To Boost Quality Control At Indian Unit | 1 | Nikkei.com | |
| 14.05. | Daiichi Sankyo's India Unit To Pay $500mn In Settlement | 1 | Nikkei.com | |
| 13.05. | Astellas, Daiichi Sankyo See New Drugs Propelling Growth | 4 | Euroinvestor | |
| 26.04. | Perosphere, Daiichi Sankyo sign PER977 clinical trial agreement | 3 | Pharma Bus Review | |
| 25.04. | Perosphere and Daiichi Sankyo Enter into a Clinical Trial Agreement to Evaluate the Efficacy and Safety of PER977 to Reverse the Anticoagulant Activity of the Investigational, Oral, Once-Daily Factor Xa Inhibitor Edoxaban | 76 | news aktuell | |
| Mount Kisco, New York And Tokyo (ots/PRNewswire) - Daiichi Sankyo to support and co-sponsor phase 1 Clinical Study Perosphere Inc. and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo)... Mehr lesen zu: Perosphere and Daiichi Sankyo Enter into a Clinical Trial Agreement to Evaluate the Efficacy and Safety of PER977 to Reverse the Anticoagulant Activity of the Investigational, Oral, Once-Daily Factor Xa Inhibitor Edoxaban | ||||
| 22.04. | Daiichi Sankyo launches dysuria therapy in China | 1 | Pharma Bus Review | |
| 22.04. | BIZ BRIEF: Daiichi Sankyo introduces drug to treat dysuria in China | - | Asahi Shimbun | |
| 18.04. | Pieris erhält zweite Meilensteinzahlung im Rahmen der Zusammenarbeit mit Daiichi Sankyo zur Entwicklung von Anticalin Therapeutika | 121 | Business Wire | |
| Die Pieris AG gab heute bekannt, dass sie den zweiten Meilenstein für das erste von zwei Programmen im Rahmen der Forschungs- und Entwicklungskollaboration mit Daiichi Sankyo Company Limited... Mehr lesen zu: Pieris erhält zweite Meilensteinzahlung im Rahmen der Zusammenarbeit mit Daiichi Sankyo zur Entwicklung von Anticalin Therapeutika | ||||
| 18.04. | Pieris Achieves Second Milestone Payment in Daiichi Sankyo Collaboration to Develop Anticalin Therapeutics | 49 | Business Wire | |
| Pieris AG has achieved the second milestone for the first of two programs in its discovery and development collaboration with Daiichi Sankyo Company Limited (hereinafter Daiichi Sankyo; headquartered... Mehr lesen zu: Pieris Achieves Second Milestone Payment in Daiichi Sankyo Collaboration to Develop Anticalin Therapeutics | ||||
| 17.04. | Daiichi Sankyo To Sell Generics In Brazil | - | Nikkei.com | |
| 17.04. | Ranbaxy, Daiichi Sankyo to team up in Brazil to expand biz | 2 | moneycontrol.com | |
| 17.04. | Daiichi Sankyo, Ranbaxy to integrate business in Brazil | 1 | Myiris | |
| 01.04. | ArQule Regains Rights Under AKT Collaboration With Daiichi Sankyo | 82 | AFX News | |
| WASHINGTON (dpa-AFX) - ArQule Inc. (ARQL) a clinical-stage biotechnology
company Monday said it has regained worldwide rights to develop compounds
covered under its AKT collaboration with... Mehr lesen zu: ArQule Regains Rights Under AKT Collaboration With Daiichi Sankyo | ||||
